Cyclosporine consensus conference: With emphasis on the treatment of psoriasis - 09/09/11
Abstract |
Cyclosporine has been in worldwide use for 15 years for patients who have undergone transplantation operations and is now being used to control inflammatory reactions in other organs (eg, joints, bowel, and skin). Neoral, a more consistently absorbed form of cyclosporine, has recently been approved by the Food and Drug Administration for the treatment of psoriasis. This report outlines the indications, contraindications, dosage recommendations, monitoring requirements, adverse events, drug interactions, interactions with other psoriasis treatments, and suggestions for cyclosporine’s use in rotational therapy. (J Am Acad Dermatol 1998;39:464-75.)
Le texte complet de cet article est disponible en PDF.Plan
Supported by a grant from Novartis Pharmaceuticals, Inc. |
|
Reprint requests: Mark Lebwohl, MD, Mt. Sinai Medical Center, Department of Dermatology, 5E 98th St, New York, NY 10029-6574. |
|
0190-9622/98/$5.00 + 0 16/1/92424 |
Vol 39 - N° 3
P. 464-475 - septembre 1998 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?